Shape the Future of Consumer Healthcare: Maxwellia Announces Exclusive Investment Opportunity
Alderley Park, Cheshire, UK – 1 October 2024
Maxwellia, the trailblazing consumer healthcare company, is inviting a select group of 100 investors to pledge their support as part of its latest £2m funding round. Supported by their current institutional shareholder base, Maxwellia’s exclusive investment opportunity opens on Wednesday 9th October and offers investors the chance to be a part of the next phase of rapid growth for one of the UK's most exciting consumer healthcare companies.
Over the past 12 months, Maxwellia has transformed from a one-brand start-up to a scale-up powerhouse with a portfolio of four innovative women’s health brands. These brands are now stocked by some of the UK’s largest pharmacy chains, including Boots, Superdrug, Tesco, and Asda. With 3x revenue growth year-on-year and a qualified pipeline of innovative products, Maxwellia continues to push the boundaries of consumer healthcare.
Innovating for the Future of Self-Care
Maxwellia specialises in turning proven prescription drugs into household medicine brands through a regulatory process known as 'switching'. As the only company in the UK dedicated to this, Maxwellia is a leader in the field. This unique business model is at the core of its rapid expansion, offering consumers easier access to trusted medications without needing a doctor’s appointment or prescription.
The UK OTC market is booming, set to reach £4bn by 2030 (1), and with calls for a renewed focus on medicine reclassification to support the over-stretched NHS (2), the time is ripe for innovating in self-care.
Anna Maxwell, CEO of Maxwellia, commented:
"Maxwellia is at a pivotal moment. We've demonstrated the power of our model with tremendous growth, and now we're ready to take it to the next level. This investment round offers a rare opportunity for investors to join us at an early stage as we shape the future of consumer healthcare. Our expertise in switching prescription medications to over-the-counter solutions is transforming self-care, and with the support of our investors, we can accelerate our plans to innovate even further."
Join Maxwellia’s Exclusive ‘100 Club’
Maxwellia is offering 100 investors the chance to land a place on their share register, unlocking its next phase of growth. Investors in this round may benefit from considerable tax breaks via the Enterprise Investment Scheme (EIS) and will see Maxwellia scale its already successful brand portfolio and drive new innovations in over-the-counter medicines.
With a lean yet highly skilled team, Maxwellia has proven its ability to turn ambition into tangible results. By joining the '100 Club', investors will directly contribute to the development of new healthcare solutions that will benefit millions, while also playing a role in shaping the future of self-care.
How to Register Your Interest
The investment round officially opens on Wednesday 8th October, but investors are encouraged to register their interest and join the exclusive waitlist today.
Learn more about this exciting investment opportunity and be part of the next wave of innovation in consumer healthcare.
You shouldn’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment.